Drug Trial Radar · NCT07549698
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 17, 2026
Primary completion
Dec 2033
Study completion Dec 2033
Sponsor
- Lead sponsor
- CRISPR Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Apr 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
Conditions
- Warm Autoimmune Hemolytic Anemia (WAIHA)
- ITP - Immune Thrombocytopenia
- Warm Autoimmune Hemolytic Anemia
- Immune Thrombocytopenic Purpura
Interventions
CTX112Biological
CTX112 (zugo-cel): CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA.Time frame: From CTX112 infusion up to 28 days post infusion.
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Boston Medical Center
Boston, Massachusetts · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Universitaetsklinikum Koeln
Cologne, Germany · Recruiting
Universitaetsklinikum Carl Gustav Carus Dresden
Dresden, Germany · Recruiting
Medizinische Hochschule Hannover (MHH)
Hanover, Germany · Recruiting
UCT University Medical Center Mainz
Mainz, Germany · Recruiting
Hospital Clinic Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Reina Sofia
Córdoba, Spain · Recruiting
Gregorio Marañón General University Hospital
Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.